Clinical Trial

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-03-15; most recent amendment 2025-01-06.
Status change: Not Yet Recruiting → Recruiting 2021-08-25
Trial Details
NCT Number NCT04803994
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Hepatocellular Carcinoma
Enrollment 434 participants
Start Date 2021-07-06
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-01-07